GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Baudax Bio BXRXQ · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Baudax Bio — daily BXRXQ Delayed
Market value
$4,359
Last close × shares
Volume
1
Shares, 30 Oct 2026

About Baudax Bio

Its shares trade under the ticker BXRXQ. It has been listed since 14 November 2019. In the fiscal year to 30 September 2022, it reported revenue of $1.3m and a net loss of $58.8m. At that date it held total assets of $10.0m and shareholders' equity of −$24.2m.

Baudax Bio, Inc. operates as a pharmaceutical company. The company is headquartered in Malvern, Pennsylvania. The company went IPO on 2019-11-14. The firm is focused on developing and commercializing products for hospital and related acute care settings. The firm's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. The company is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. The company is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.

Figures and description from our data supplier, not checked against the company's own report.

More about Baudax Bio →

Latest on Baudax Bio

Our reporting

We have not reported on Baudax Bio yet.

Next results

11 Nov 2026

Due on 11 Nov 2026. Analysts expect earnings of -270.67 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Baudax Bio's ticker?

Baudax Bio trades as BXRXQ on its US listing, under ISIN US07160F4046.

What was Baudax Bio's last closing price?

0.00 on 30 Oct 2026. The figure is in USD and is never converted.

When does Baudax Bio next report results?

Results are expected on 11 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.